SCCA | Strategic Alliance Partners

Latest from SCCA

Promises and Pitfalls of MRD as a Potential Surrogate End Point in AML

March 18, 2021

Jerald Radich, MD, highlights the role minimal residual disease in acute myeloid leukemia, how different technological advanced have increased the application of MRD-based strategies, and ongoing efforts that are being made to address remaining questions.